在使用免疫检查点抑制剂的癌症患者中,同时使用他类药物和生存率:元分析
Yonghe Liao1, Yuxuan Lin2, Xinqi Ye3
1School of Pharmaceutical Science, Guangxi Medical University, Nanning, PR China.
JCO oncology practice
|January 8, 2025
概括
在接受免疫检查点抑制剂 (ICI) 的癌症患者同时使用他类药物与改善整体存活率和无进展存活率有关. 这一发现表明,他类药物可能会提高ICI治疗的有效性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗.
- 同时服用的药物,如他类药物,在调节ICI疗效方面的作用正在研究中.
- 了解改善ICI治疗结果的因素对于患者管理至关重要.
研究的目的:
- 评估他类药物在接受免疫检查点抑制剂 (ICI) 治疗的癌症患者使用的预后意义.
- 为治疗决策提供基于证据的指导,关于在ICI治疗中同时使用他类药物的治疗.
- 为了澄清他类药物对该患者群体生存结果的影响.
主要方法:
- 在2024年6月20日之前进行了系统的文献搜索.
- 包括英语研究报告总生存 (OS) 和无进展生存 (PFS) 的危险比率 (HRs).
- 进行的元分析计算了聚合HR和95%信心区间 (CI).
主要成果:
- 对25项涉及46,154名癌症患者的研究进行了元分析.
- 同时使用他类药物与改善的OS相关 (HR,0.80 [95% CI,0.71至0.92]).
- 同时使用他类药物也与改善PFS有关 (HR,0.80 [95% CI,0.69至0.92]).
结论:
- 同时使用他类药物在接受ICI治疗的癌症患者的预后改善方面表现出积极的关联.
- 类他类药物显示出作为辅助疗法的潜力,以提高ICI治疗结果.
- 需要进一步的随机对照试验来确认他类药物在ICI治疗中的作用.
更多相关视频
相关概念视频
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K


